A Phase 1, Open-Label, Q21 Day Dose Escalation, Multi-Center Study of TPI 287 in Patients With Advanced Malignancies
The primary objective of this study is to determine the maximum tolerated dose of TPI 287
administered every 21 days for Phase II clinical trials.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To determine the maximum tolerated dose of TPI 287 administered every 21 days
Sandra Silberman, MD
Tapestry Pharmaceuticals, Inc.
United States: Food and Drug Administration
|Rocky Mountain Cancer Center||Denver, Colorado 80218|